Clearside Biomedical, Inc. Names Stephen H. Lang Vice President, Commercial Operations

  Clearside Biomedical, Inc. Names Stephen H. Lang Vice President, Commercial
  Operations

Business Wire

ALPHARETTA, Ga. -- March 4, 2013

Clearside Biomedical, Inc., a privately held ophthalmic company developing and
commercializing targeted therapeutics for the treatment of sight-threatening
diseases, today announced the appointment of Stephen H. Lang as Vice
President, Commercial Operations.

Lang has more than 30 years of experience in the ophthalmic pharmaceutical
industry, specializing in the areas of sales, marketing, sales operations and
business development.

“Steve’s broad knowledge of ophthalmology and experience in building and
leading commercial teams in the U.S. along with his global experience are
invaluable assets to us,” said Daniel White, president and CEO. “He will be a
very important part of the leadership team we are building at Clearside
Biomedical.”

Lang served from 2006 until 2012 as Vice President, Sales, at ISTA
Pharmaceuticals, Inc., where he led the building and expansion of ISTA’s sales
organization and exceeded US $160 million in annual sales.

Prior to joining ISTA, Lang was Senior Vice President, U.S. Sales and
Marketing, for Novartis Ophthalmics, Inc., where his team launched Visudyne®
(Valeant Pharmaceuticals International, Inc.; NYSE: VRX). Visudyne® was the
first available drug therapy for people with a form of age-related macular
degeneration known as classic "wet AMD." Before joining Novartis, Lang served
for more than 16 years in various positions with Allergan, Inc. (NYSE: AGN),
including sales, marketing, national accounts and global business development.
He obtained his B.B.A. in Management from Georgia Southern University.

“I look forward to helping bring Clearside’s breakthrough products to market,”
said Lang, noting that the company’s CLS1001 (triamcinolone acetonide)
Suprachoroidal Injectable Suspension is being developed to treat sympathetic
ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions
unresponsive to topical corticosteroids. “Using our proprietary microinjection
platform to deliver drugs to the back of the eye via the suprachoroidal space
holds great promise to help millions of people suffering from debilitating eye
diseases. We offer a novel approach to posterior segment care that will be the
foundation of Clearside’s commercial success.”

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a
clinical-stage ophthalmic pharmaceutical company that develops and
commercializes targeted therapeutics to treat sight-threatening diseases.
Clearside treats the pathological changes to the blood retinal barrier that
lead to retinal blindness by delivering therapeutics through the
suprachoroidal space to the retina and choroid using a proprietary
microinjection dosage form. Clearside Biomedical was founded by an executive
team with extensive development and revenue growth expertise. This team
strives for better delivery and performance of its therapeutic agents to
improve the standard of care for patients with retinal and choroidal disease.
Visit www.clearsidebiomedical.com for more information.

Contact:

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
charlie.deignan@clearsidebio.com
 
Press spacebar to pause and continue. Press esc to stop.